Improving the adherence to antiretroviral therapy, a difficult but essential task for a successful HIV treatment-clinical points of view and practical considerations

Frontiers in Pharmacology

Volumn 8, Issue NOV, 2017, Pages

  Iacob, Simona A ^a,b   Iacob, Diana G ^b   Jugulete, Gheorghita ^a,b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b 'Matei Bal ' Institute for Infectious Diseases   (Romania)

Author keywords

Adherence; Adverse reactions; Antiretroviral drugs; Antiretroviral treatment; HIV; Key affected population

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; AGED; ALCOHOL ABUSE; ALCOHOLISM; ANTIRETROVIRAL THERAPY; BONE MARROW SUPPRESSION; CHILD; DEPRESSION; DIRECTLY OBSERVED THERAPY; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG USE; FEMALE; GASTROINTESTINAL SYMPTOM; HARM REDUCTION; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; INSOMNIA; LIPODYSTROPHY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; MYOPATHY; NEPHROTOXICITY; NIGHTMARE; OPIATE SUBSTITUTION TREATMENT; OSTEOPOROSIS; PANCREATITIS; PANDEMIC; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT MONITORING; PERIPHERAL NEUROPATHY; QUANTITATIVE ANALYSIS; REVIEW; SELF REPORT; SIDE EFFECT; SOCIAL ISOLATION; SOCIAL SUPPORT;

EID: 85035002924     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2017.00831     Document Type: Review

References (88)

1. ABC Project Team (2018). Ascertaining Barriers for Compliance: Policies for Safe, Effective and Cost-Effective Use of Medicines in Europe Final Report of the ABC Project
2. Aharonovich, E., Greenstein, E., O'Leary, A., Johnston, B., Seol, S. G., and Hasin, D. S. (2012). HealthCall: technology-based extension of motivational interviewing to reduce non-injection drug use in HIV primary care patients ? a pilot study. AIDS Care 24, 1461-1469. doi: 10.1080/09540121.2012.663882
3. Altice, F. L., Maru DS-Bruce, R. D., Springer, S. A., and Friedland, G. H. (2007). Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin. Infect. Dis. 45, 770-778. doi: 10.1086/521166
4. Arage, G., Tessema, G. A., and Kassa, H. (2014). Adherence to antiretroviral therapy and its associated factors among children at South Wollo Zone Hospitals, Northeast Ethiopia: a cross-sectional study. BMC Public Health. 14:365. doi: 10.1186/1471-2458-14-365
5. Arnsten, J. H., Demas, P. A., Grant, R. W., Gourevitch, M. N., Farzadegan, H., Howard, A. A., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J. Gen. Intern. Med. 17, 377-381. doi: 10.1007/s11606-002-0044-3
6. Arnsten, J., Demas, P., Farzadegan, H., Grant, R., Gourevitch, M., Chang, C., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin. Infect. Dis. 33, 1417-1423. doi: 10.1086/323201
7. Azmeraw, D., and Wasie, B. (2012). Factors associated with adherence to highly active antiretroviral therapy among children in two referral hospitals, northwest Ethiopia. Ethiop. Med. J. 50, 115-124
8. Bangsberg, D. R., Mundy, L. M., and Tulsky, J. P. (2001). Expanding directly observed therapy: tuberculosis to human immunodeficiency virus. Am. J. Med. 110, 664-666. doi: 10.1016/S0002-9343(01)00729-X
9. Barai, N., Monroe, A., Lesko, C., Lau, B., Hutton, H., Yang, C., et al. (2017). The association between changes in alcohol use and changes in antiretroviral therapy adherence and viral suppression among women living with HIV. AIDS Behav. 21, 1836-1845. doi: 10.1007/s10461-016-1580-x
10. Bartlett, J. A. (2002). Addressing the challenges of adherence. J. Acquir. Immune. Defic. Syndr. 29(Suppl. 1), S2-S10. doi: 10.1097/00126334-200202011-00002
11. Berkman, L. F., and Syme, S. L. (1979). Social networks, host resistance, and mortality: a nine-year follow-up study of Alameda County residents. Am. J. Epidemiol. 109, 186-204. doi: 10.1093/oxfordjournals.aje.a112674
12. Bhaskaran, K., Hamouda, O., Sannes, M., Boufassa, F., Johnson, A. M., Lambert, P. C., et al. (2008). Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300:51. doi: 10.1001/jama.300.1.51
13. Bierman, W. F., van Agtmael, M. A., Nijhuis, M., Danner, S. A., and Boucher, C. A. (2009). HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23, 279-291. doi: 10.1097/QAD.0b013e32831c54e5
14. Cantudo-Cuenca, M. R., Jiménez-Galán, R., Almeida-González C, V., and Morillo-Verdugo, R. (2014). Concurrent use of comedications reduces adherence to antiretroviral therapy among HIV-infected patients. J. Manag. Care Pharm. 20, 844-850. doi: 10.18553/jmcp.2014.20.8.844
15. Carr, A., Miller, J., Law, M., and Cooper, D. A. (2000). A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14, F25-F32. doi: 10.1097/00002030-200002180-00001
16. Centers for Disease Control and Prevention (2014). Understanding the HIV care Continuum. 2014. (cited Oct 14, 2017). Available online at: http://www.cdc.gov/hiv/pdf/dhap_continuum.pdf
17. Chaiyachati, K. H., Ogbuoji, O., Price, M., Suthar, A. B., Negussie, E. K., and Bärnighausen, T. (2014). Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. Wolters Kluwer Heal. 28, 187-204. doi: 10.1097/QAD.0000000000000252
18. Chesney, M. (2003). Adherence to HAART regimens. AIDS Patient Care STDS. 17, 169-177. doi: 10.1089/108729103321619773
19. Clay, P. G., Nag, S., Graham, C. M., and Narayanan, S. (2015). Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine 94:e1677. doi: 10.1097/MD.0000000000001677
20. Cluver, L. D., Orkin, F. M., Boyes, M. E., and Sherr, L. (2014). Cash plus care. AIDS 28, S389-S397. doi: 10.1097/QAD.0000000000000340
21. Cluver, L. D., Orkin, F. M., Meinck, F., Boyes, M. E., and Sherr, L. (2016). Structural drivers and social protection: mechanisms of HIV risk and HIV prevention for South African adolescents. J. Int. AIDS Soc. 19:20646. doi: 10.7448/IAS.19.1.20646
22. Conn, V. S., and Ruppar, T. M. (2017). Medication adherence outcomes of 771 intervention trials: systematic review and meta-analysis. Prev. Med. 99, 269-276. doi: 10.1016/j.ypmed.2017.03.008
23. Cook, R. L., Sereika, S. M., Hunt, S. C., Woodward, W. C., Erlen, J. A., and Conigliaro, J. (2001). Problem drinking and medication adherence among persons with HIV infection. J. Gen. Intern. Med. 16, 83-88. doi: 10.1111/j.1525-1497.2001.00122.x
24. Ebuy, H., Yebyo, H., and Alemayehu, M. (2015). Level of adherence and predictors of adherence to the Option B+ PMTCT programme in Tigray, northern Ethiopia. Int. J. Infect. Dis. 33, 123-129. doi: 10.1016/j.ijid.2014.12.026
25. Elovainio, M., Hakulinen, C., Pulkki-Råback, L., Virtanen, M., Josefsson, K., Jokela, M., et al. (2017). Contribution of risk factors to excess mortality in isolated and lonely individuals: an analysis of data from the UK Biobank cohort study. Lancet Public Heal. 2, e260-e266. doi: 10.1016/S2468-2667(17)30075-0
26. Fernandes, R. M., Cary, M., Duarte, G., Jesus, G., Alarcão, J., Torre, C., et al. (2017). Effectiveness of needle and syringe programmes in people who inject drugs-An overview of systematic reviews. BMC Public Health 17:309. doi: 10.1186/s12889-017-4210-2
27. Flanigan, T. P., and Mitty, J. A. (2006). The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficult. Clin. Infect. Dis. 42, 1636-1638. doi: 10.1086/503916
28. Ford, N., Nachega, J. B., Engel, M. E., and Mills, E. J. (2009). Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet 374, 2064-2071. doi: 10.1016/S0140-6736(09)61671-8
29. Galvan, F. H., Bing, E. G., Fleishman, J. A., London, A. S., Caetano, R., Burnam, M. A., et al. (2002). The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J. Stud. Alcohol. 63, 179-186. doi: 10.15288/jsa.2002.63.179
30. Gifford, A. L., Bormann, J. E., Shively, M. J., Wright, B. C., Richman, D. D., and Bozzette, S. A. (2000). Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J. Acquir. Immune Defic. Syndr. 23, 386-395. doi: 10.1097/00042560-200004150-00005
31. Gimeno-Gracia, M., Crusells-Canales, M. J., Javier Armesto-Gómez, F., and Rabanaque-Hernández, M. J. (2015). Prevalence of concomitant medications in older HIV+ patients and comparison with general population. HIV Clin. Trials. 16, 117-124. doi: 10.1179/1528433614Z.0000000012
32. Gokarn, A., Narkhede, M. G., Pardeshi, G. S., Kondiba, M., and Doibale (2012). Adherence to antiretroviral therapy. J. Assoc. Phys. India 60, 16-20
33. Golrokhy, R., Koochak, H. E., Babaii, A., Pourdast, A., Rasoolinejad, M., Moghadam, S. R. J., et al. (2017). Prevalence of Adverse Drug Reactions to Highly Active Antiretroviral Therapy (HAART) among HIV-Positive Patients in Imam Khomeini Hospital of Tehran, Iran. Infect. Disord. Drug Targets 17, 116-119. doi: 10.2174/1871526517666170117111350
34. Gonzalez, A., Barinas, J., and O'Cleirigh, C. (2011). Substance use: impact on adherence and HIV medical treatment. Curr. HIV/AIDS Rep. 8, 223-234. doi: 10.1007/s11904-011-0093-5
35. Graham, S. M., Mugo, P., Gichuru, E., Thiong'o, A., Macharia, M., Okuku, H. S., et al. (2013). Adherence to antiretroviral therapy and clinical outcomes among young adults reporting high-risk sexual behavior, including men who have sex with men, in coastal kenya. AIDS Behav. 17, 1255-1265. doi: 10.1007/s10461-013-0445-9
36. Grossberg, R., and Gross, R. (2007). Use of pharmacy refill data as a measure of antiretroviral adherence. Curr. HIV/AIDS Rep. 4, 187-191. doi: 10.1007/s11904-007-0027-4
37. Haberer, J. E., Kahane, J., Kigozi, I., Emenyonu, N., Hunt, P., Martin, J., et al. (2010). Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav. 14, 1340-1346. doi: 10.1007/s10461-010-9799-4
38. Haberer, J. E., Sabin, L., Amico, K. R., Orrell, C., Galárraga, O., Tsai, A. C., et al. (2017). Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. J. Int. AIDS Soc. 20:21371. doi: 10.7448/IAS.20.1.21371
39. Hayashi, K., Wood, E., Kerr, T., Dong, H., Nguyen, P., Puskas, C. M., et al. (2016). Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study. BMC Infect. Dis. 16, 455. doi: 10.1186/s12879-016-1749-y
40. Hinkin, C. H., Barclay, T. R., Castellon, S. A., Levine, A. J., Durvasula, R. S., Marion, S. D., et al. (2007). Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 11, 185-194. doi: 10.1007/s10461-006-9152-0
41. Hinkin, C. H., Hardy, D. J., Mason, K. I., Castellon, S. A., Durvasula, R. S., Lam, M. N., et al. (2004). Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS 18(Suppl. 1), S19-S25
42. Horne, R., and Weinman, J. (1999). Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J. Psychosom. Res. 47, 555-567. doi: 10.1016/S0022-3999(99)00057-4
43. Inciardi, J. A. (1995). Crack, crack house sex, and HIV risk. Arch. Sex. Behav. 24, 249-269. doi: 10.1007/BF01541599
44. Johnson, C. J., Heckman, T. G., Hansen, N. B., Kochman, A., and Sikkema, K. J. (2009). Adherence to antiretroviral medication in older adults living with HIV/AIDS: a comparison of alternative models. AIDS Care 21, 541-551. doi: 10.1080/09540120802385611
45. Kalichman, S. C., Ramachandran, B., and Catz, S. (1999). Adherence to combination antiretroviral therapies in HIV patients of low health literacy. J. Gen. Intern. Med. 14, 267-273. doi: 10.1046/j.1525-1497.1999.00334.x
46. Kay, E. S., Batey, D. S., and Mugavero, M. J. (2016). The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future. AIDS Res. Ther. 13, 35. doi: 10.1186/s12981-016-0120-0
47. Kelly, C. M., van Oosterhout, J. J., Ngwalo, C., Stewart, R. C., Benjamin, L., Robertson, K. R., et al. (2014). HIV Associated Neurocognitive Disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study. PLoS ONE 9:e98962. doi: 10.1371/journal.pone.0098962
48. Kim, S.-H., Gerver, S. M., Fidler, S., and Ward, H. (2014). Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS 28, 1945-1956. doi: 10.1097/QAD.0000000000000316
49. Kirsten, I., Sewangi, J., Kunz, A., Dugange, F., Ziske, J., Jordan-Harder, B., et al. (2011). Adherence to combination prophylaxis for prevention of mother-to-child-transmission of HIV in Tanzania. PLoS ONE 6:e21020. doi: 10.1371/journal.pone.0021020
50. Kumar, V., and Encinosa, W. (2009). Effects of antidepressant treatment on antiretroviral regimen adherence among depressed HIV-infected patients. Psychiatr. Q. 80, 131-141. doi: 10.1007/s11126-009-9100-z
51. Lambers, F. A. E., Stolte, I. G., van den Berg, C. H. S. B., Coutinho, R. A., and Prins, M. (2011). Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam. Int. J. Drug Policy. 22, 210-218. doi: 10.1016/j.drugpo.2011.02.004
52. Langebeek, N., Gisolf, E. H., Reiss, P., Vervoort, S. C., Hafsteinsdóttir, T. B., Richter, C., et al. (2014). Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 12:142. doi: 10.1186/s12916-014-0142-1
53. Liu, A. Y., Hessol, N. A., Vittinghoff, E., Amico, K. R., Kroboth, E., Fuchs, J., et al. (2014). Medication adherence among men who have sex with men at risk for HIV infection in the united states: implications for pre-exposure prophylaxis implementation. AIDS Patient Care STDS 28, 622-627. doi: 10.1089/apc.2014.0195
54. Llibre, J. M., Chien-Ching, H., Brinson, C., Castelli, F., Wynn, B., and Vandermeulen, K. A. M. (2017). "Phase III Sword 1& 2: switch to DTG+RPV maintains virologic suppression through 48 Wks," in CROI Conference (Washington,DC: CROI Seattle), Abstract Number: 44LB
55. Macalino, G. E., Hogan, J. W., Mitty, J. A., Bazerman, L. B., DeLong, A. K., Loewenthal, H., et al. (2007). A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 21, 1473-1477. doi: 10.1097/QAD.0b013e32811ebf68
56. Margolis, A. M., Heverling, H., Pham, P. A., and Stolbach, A. (2014). A review of the toxicity of HIV medications. J. Med. Toxicol. 10, 26-39. doi: 10.1007/s13181-013-0325-8
57. McCoy, S. I., Strauss, R. P., MacDonald, P. D. M., Leone, P. A., Eron, J. J., and Miller, W. C. (2009). Social support and delays seeking care after HIV diagnosis, North Carolina, 2000-2006. AIDS Care 21, 1148-1156. doi: 10.1080/09540120902730021
58. Menezes de Pádua, C. A., and Moura, C. S. (2014). Availability of data on adverse reactions to antiretroviral drugs in medical charts according to the naranjo algorithm: an example of a brazilian historical cohort. Clin. Drug Investig. 34, 395-402. doi: 10.1007/s40261-014-0187-0
59. Millar, B. M., Starks, T. J., Gurung, S., and Parsons, J. T. (2017). The Impact of Comorbidities, depression, and substance use problems on quality of life among older adults living with, HIV. AIDS Behav. 21, 1684-1690. doi: 10.1007/s10461-016-1613-5
60. Mills, E. J., Nachega, J. B., Buchan, I., Orbinski, J., Attaran, A., Singh, S., et al. (2006). Adherence to antiretroviral therapy in Sub-Saharan Africa and North America. JAMA 296, 679. doi: 10.1001/jama.296.6.679
61. Mountain, E., Mishra, S., Vickerman, P., Pickles, M., Gilks, C., and Boily, M. (2014). Antiretroviral therapy uptake, attrition, adherence and outcomes among HIV-infected female sex workers: a systematic review and meta-analysis. PLoS ONE 9:e105645. doi: 10.1371/journal.pone.0105645
62. Nieuwkerk, P. T., Sprangers, M. A., Burger, D. M., Hoetelmans, R. M., Hugen, P. W., Danner, S. A., et al. (2001). Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch. Intern. Med. 161, 1962-1968. doi: 10.1001/archinte.161.16.1962
63. Orrell, C., Cohen, K., Leisegang, R., Bangsberg, D. R., Wood, R., and Maartens, G. (2017). Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes? AIDS Res. Ther. 14, 20. doi: 10.1186/s12981-017-0138-y
64. Ortego, C., Huedo-Medina, T. B., Llorca, J., Sevilla, L., Santos, P., Rodríguez, E., et al. (2011). Adherence to Highly Active Antiretroviral Therapy (HAART): a meta-analysis. AIDS Behav. 15, 1381-1396. doi: 10.1007/s10461-011-9942-x
65. Ortego, C., Huedo-Medina, T. B., Santos, P., Rodrígue, E., Sevilla, L., Warren, M., et al. (2012). Sex differences in adherence to highly active antiretroviral therapy: a meta-analysis. AIDS Care 24, 1519-1534. doi: 10.1080/09540121.2012.672722
66. Paterson, D. L., Swindells, S., Mohr, J., Brester, M., Vergis, E. N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133, 21-30. doi: 10.7326/0003-4819-133-1-200007040-00004
67. Reblin, M., and Uchino, B. N. (2008). Social and emotional support and its implication for health. Curr. Opin. Psychiatry 21, 201-205. doi: 10.1097/YCO.0b013e3282f3ad89
68. Samet, J. H., Horton, N. J., Meli, S., Freedberg, K. A., and Palepu, A. (2004). Alcohol consumption and antiretroviral adherence among HIV-infected persons with alcohol problems. Alcohol Clin. Exp. Res. 28, 572-577. doi: 10.1097/01.ALC.0000122103.74491.78
69. Shi, L., Liu, J., Koleva, Y., Fonseca, V., Kalsekar, A., and Pawaskar, M. (2010). Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 28, 1097-1107. doi: 10.2165/11537400-000000000-00000
70. Sidat, M., Fairley, C., and Grierson, J. (2007). Experiences and perceptions of patients with 100% adherence to highly active antiretroviral therapy: a qualitative study. AIDS Patient Care STDS 21, 509-520. doi: 10.1089/apc.2006.0201
71. Spire, B., Lucas, G. M., and Carrieri, M. P. (2007). Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int. J. Drug Policy 18, 262-270. doi: 10.1016/j.drugpo.2006.12.014
72. Steiner, J. F., and Prochazka A, V. (1997). The assessment of refill compliance using pharmacy records: methods, validity, and applications. J. Clin. Epidemiol. 50, 105-116. doi: 10.1016/S0895-4356(96)00268-5
73. Stirratt, M. J., Dunbar-Jacob, J., Crane, H. M., Simoni, J. M., Czajkowski, S., Hilliard, M. E., et al. (2015). Self-report measures of medication adherence behavior: recommendations on optimal use. Transl. Behav. Med. 5, 470-482. doi: 10.1007/s13142-015-0315-2
74. Takada, S., Weiser, S. D., Kumbakumba, E., Muzoora, C., Martin, J. N., Hunt, P. W., et al. (2014). The dynamic relationship between social support and HIV-related stigma in rural Uganda. Ann. Behav. Med. 48, 26-37. doi: 10.1007/s12160-013-9576-5
75. UNAIDS (2014). The Gap Report. UNAIDS
76. UNAIDS (2013). UNAIDS Report on the Global AIDS Epidemic 2013. UNAIDS
77. UNAIDS (2015). AIDS by the Numbers 2015. Available online at: http://www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf
78. Uthman, O. A., Oladimeji, O., and Nduka, C. (2017). Adherence to antiretroviral therapy among HIV-infected prisoners: a systematic review and meta-analysis. AIDS Care 29, 489-497. doi: 10.1080/09540121.2016.1223799
79. Viswanathan, S., Detels, R., Mehta, S. H., Macatangay, B. J. C., Kirk, G. D., and Jacobson, L. P. (2015). Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 19, 601-611 doi: 10.1007/s10461-014-0927-4
80. Vrijens, B., De Geest, S., Hughes, D. A., Przemyslaw, K., Demonceau, J., Ruppar, T., et al. (2012). A new taxonomy for describing and defining adherence to medications. Br. J. Clin. Pharmacol. 73, 691-705. doi: 10.1111/j.1365-2125.2012.04167.x
81. Wagner, G. J., and Rabkin, J. G. (2000). Measuring medication adherence: are missed doses reported more accurately than perfect adherence? AIDS Care 12, 405-408. doi: 10.1080/09540120050123800
82. Wanchu, A., Kaur, R., Bambery, P., and Singh, S. (2007). Adherence to generic reverse transcriptase inhibitor-based antiretroviral medication at a Tertiary Center in North India. AIDS Behav. 11, 99-102. doi: 10.1007/s10461-006-9101-y
83. Wechsberg, W. M., Golin, C., El-Bassel, N., Hopkins, J., and Zule, W. (2012). Current interventions to reduce sexual risk behaviors and crack cocaine use among HIV-infected individuals. Curr. HIV/AIDS Rep. 9, 385-393. doi: 10.1007/s11904-012-0131-y
84. WHO (2001). Adherence to Long-term Therapies: Policy for Action. Meeting Report. Available online at: http://www.who.int/chp/knowledge/publications/adherencerep.pdf
85. Wing, E. J. (2016). HIV and aging. Int. J. Infect. Dis. 53, 61-68. doi: 10.1016/j.ijid.2016.10.004
86. Wohl, D. A., Stephenson, B. L., Golin, C. E., Nichole Kiziah, C., Rosen, D., Ngo, B., et al. (2003). Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin. Infect. Dis. 36, 1572-1576. doi: 10.1086/375076
87. Wood, E., Montaner, J. S. G., Yip, B., Tyndall, M. W., Schechter, M. T., O'Shaughnessy M, V., et al. (2003). Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 169, 656-661
88. Yun, L. W. H., Maravi, M., Kobayashi, J. S., Barton, P. L., and Davidson, A. J. (2005). Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J. Acquir. Immune. Defic. Syndr. 38, 432-438. doi: 10.1097/01.qai.0000147524.19122.fd